The estimated Net Worth of Kevin M King is at least $24.4 Milione dollars as of 4 March 2022. Mr. King owns over 6,815 units of iRhythm Technologies Inc stock worth over $18,739,078 and over the last 8 years he sold IRTC stock worth over $904,146. In addition, he makes $4,774,140 as President, Chief Executive Officer e Director at iRhythm Technologies Inc.
Kevin has made over 22 trades of the iRhythm Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 6,815 units of IRTC stock worth $904,146 on 4 March 2022.
The largest trade he's ever made was exercising 110,000 units of iRhythm Technologies Inc stock on 10 July 2017 worth over $453,200. On average, Kevin trades about 27,133 units every 45 days since 2016. As of 4 March 2022 he still owns at least 250,422 units of iRhythm Technologies Inc stock.
You can see the complete history of Mr. King stock trades at the bottom of the page.
Kevin M. King serves as President, Chief Executive Officer, Director of the Company. Mr. King has nearly three decades of experience in the healthcare and IT industries in leadership roles. In January 2007, Mr. King joined Affymetrix, Inc., a publicly traded technology innovator in the field of genetic analysis, as President of Life Sciences Business and Executive Vice President. Mr. King was promoted to President of Affymetrix in September 2007 and then served as President and Chief Executive Officer and a director of Affymetrix from January 2009 until June 2011, leading Affymetrix on a growth strategy into new markets for downstream validation and molecular diagnostics and overseeing several acquisitions. Prior to Affymetrix, from February 2005 until June 2006, Mr. King served as President and Chief Executive Officer of Thomson Healthcare, an information services business which focused on a range of healthcare-related businesses. From March 1997 until November 2004, Mr. King was a senior executive at GE Healthcare, where he led several business units including Magnetic Resonance Imaging and Global Clinical Systems Business. Mr. King began his career at Hewlett-Packard’s Medical Products Group and during his 14-year tenure held leadership roles in Sales, Marketing, R&D, and Business Development. Mr. King holds a B.A. in Economics and Biology from the University of Massachusetts and an M.B.A. from New Hampshire College.
As the President, Chief Executive Officer e Director of iRhythm Technologies Inc, the total compensation of Kevin King at iRhythm Technologies Inc is $4,774,140. There are no executives at iRhythm Technologies Inc getting paid more.
Kevin King is 63, he's been the President, Chief Executive Officer e Director of iRhythm Technologies Inc since 2012. There are 5 older and 17 younger executives at iRhythm Technologies Inc. The oldest executive at iRhythm Technologies Inc is Ralph Snyderman, 80, who is the Independent Director.
Kevin's mailing address filed with the SEC is C/O INOGEN, INC, 859 WARD DRIVE, GOLETA, CA, 93111.
Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi e Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.
irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
iRhythm Technologies Inc executives and other stock owners filed with the SEC include: